374 related articles for article (PubMed ID: 32761199)
1. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests.
Peterse EFP; Meester RGS; de Jonge L; Omidvari AH; Alarid-Escudero F; Knudsen AB; Zauber AG; Lansdorp-Vogelaar I
J Natl Cancer Inst; 2021 Feb; 113(2):154-161. PubMed ID: 32761199
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population.
Knudsen AB; Lansdorp-Vogelaar I; Rutter CM; Savarino JE; van Ballegooijen M; Kuntz KM; Zauber AG
J Natl Cancer Inst; 2010 Aug; 102(16):1238-52. PubMed ID: 20664028
[TBL] [Abstract][Full Text] [Related]
3. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.
Knudsen AB; Zauber AG; Rutter CM; Naber SK; Doria-Rose VP; Pabiniak C; Johanson C; Fischer SE; Lansdorp-Vogelaar I; Kuntz KM
JAMA; 2016 Jun; 315(23):2595-609. PubMed ID: 27305518
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
5. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
[TBL] [Abstract][Full Text] [Related]
6. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
8. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model.
Knudsen AB; Hur C; Gazelle GS; Schrag D; McFarland EG; Kuntz KM
Ann Intern Med; 2012 Nov; 157(9):611-20. PubMed ID: 23128861
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of screening strategies for colorectal cancer.
Barzi A; Lenz HJ; Quinn DI; Sadeghi S
Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
[TBL] [Abstract][Full Text] [Related]
11. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
Sharaf RN; Ladabaum U
Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
[TBL] [Abstract][Full Text] [Related]
13. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality.
D'Andrea E; Ahnen DJ; Sussman DA; Najafzadeh M
Cancer Med; 2020 Jan; 9(2):824-836. PubMed ID: 31777197
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of colorectal cancer screening - an overview.
Lansdorp-Vogelaar I; Knudsen AB; Brenner H
Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):439-49. PubMed ID: 20833348
[TBL] [Abstract][Full Text] [Related]
15. Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations.
Vanness DJ; Knudsen AB; Lansdorp-Vogelaar I; Rutter CM; Gareen IF; Herman BA; Kuntz KM; Zauber AG; van Ballegooijen M; Feuer EJ; Chen MH; Johnson CD
Radiology; 2011 Nov; 261(2):487-98. PubMed ID: 21813740
[TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.
Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I
Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616
[TBL] [Abstract][Full Text] [Related]
17. Colorectal Cancer: Cost-effectiveness of Colonoscopy versus CT Colonography Screening with Participation Rates and Costs.
van der Meulen MP; Lansdorp-Vogelaar I; Goede SL; Kuipers EJ; Dekker E; Stoker J; van Ballegooijen M
Radiology; 2018 Jun; 287(3):901-911. PubMed ID: 29485322
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness and projected national impact of colorectal cancer screening in France.
Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
[TBL] [Abstract][Full Text] [Related]
19. Would initiating colorectal cancer screening from age of 45 be cost-effective in Germany? An individual-level simulation analysis.
Lwin MW; Cheng CY; Calderazzo S; Schramm C; Schlander M
Front Public Health; 2024; 12():1307427. PubMed ID: 38454984
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]